Simcere Pharmaceutical Group Limited (HKG:2096)

Market Cap	29.80B +55.8%
Revenue (ttm)	7.79B +12.1%
Net Income	964.48M
EPS	0.39
Shares Out	2.58B
PE Ratio	29.40
Forward PE	20.67
Dividend	0.18 (1.58%)
Ex-Dividend Date	Jun 18, 2025

Volume	2,442,000
Average Volume	5,007,787
Open	11.66
Previous Close	11.67
Day's Range	11.52 - 11.72
52-Week Range	7.07 - 15.08
Beta	0.90
RSI	43.04
Earnings Date	Mar 25, 2026

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 6,815
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2096

Financial Performance

In 2024, HKG:2096's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY